[go: up one dir, main page]

MX2007008136A - Metodo para invertir la resistencia multiple en celulas animales. - Google Patents

Metodo para invertir la resistencia multiple en celulas animales.

Info

Publication number
MX2007008136A
MX2007008136A MX2007008136A MX2007008136A MX2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A
Authority
MX
Mexico
Prior art keywords
animal cells
multiple resistance
reversing multiple
reversing
resistance
Prior art date
Application number
MX2007008136A
Other languages
English (en)
Inventor
Per Sonne Holm
Original Assignee
Per Sonne Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Per Sonne Holm filed Critical Per Sonne Holm
Publication of MX2007008136A publication Critical patent/MX2007008136A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de un virus, preferiblemente un adenovirus, para invertir resistencia en celulas.
MX2007008136A 2004-12-31 2006-01-02 Metodo para invertir la resistencia multiple en celulas animales. MX2007008136A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004063639 2004-12-31
US65108505P 2005-02-08 2005-02-08
PCT/EP2006/000009 WO2006070023A2 (en) 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells

Publications (1)

Publication Number Publication Date
MX2007008136A true MX2007008136A (es) 2008-02-12

Family

ID=36582063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008136A MX2007008136A (es) 2004-12-31 2006-01-02 Metodo para invertir la resistencia multiple en celulas animales.

Country Status (10)

Country Link
US (4) US20100310554A1 (es)
EP (1) EP1831382B1 (es)
JP (1) JP5584393B2 (es)
KR (1) KR101527213B1 (es)
CN (1) CN101128593B (es)
AU (1) AU2006203736B2 (es)
CA (1) CA2592699C (es)
MX (1) MX2007008136A (es)
SG (1) SG158133A1 (es)
WO (1) WO2006070023A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099859A2 (de) 2002-05-27 2003-12-04 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
WO2006070024A2 (de) * 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
KR102063195B1 (ko) * 2012-02-07 2020-01-07 글로벌 바이오 테라퓨틱스, 인크. 핵산 전달의 구획화된 방법 및 이의 조성물 및 용도
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3033414A4 (en) * 2013-08-12 2017-03-22 Invivosciences Inc. Automated cell culture system and method
EP4043021A3 (en) 2014-09-24 2022-11-23 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US10813957B2 (en) * 2016-10-07 2020-10-27 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
JP7114571B2 (ja) * 2017-03-31 2022-08-08 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
MX2019014059A (es) * 2017-05-24 2020-07-28 Epicentrx Inc Adenovirus antiangiogenico.
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
CN113774031B (zh) * 2020-06-10 2024-04-02 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用
EP4410971A4 (en) * 2021-09-30 2025-06-04 FUJIFILM Corporation METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030534A1 (en) * 1995-03-24 1996-10-03 Genzyme Corporation Adenovirus vectors for gene therapy
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
DK1199368T3 (da) * 1998-07-07 2004-04-13 Transgene Sa Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
AU6425800A (en) * 1999-06-30 2001-01-22 Max-Delbruck-Centrum Fur Molekulare Medizin Agents for the diagnosis, prognosis and treatment of malignant diseases
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US6635476B1 (en) * 1999-10-15 2003-10-21 Canji, Inc. Targeted vectors
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
KR100491299B1 (ko) * 2001-09-29 2005-05-24 학교법인연세대학교 개선된 질환 치료 효과를 갖는 재조합 아데노바이러스 및그를 포함하는 약제학적 조성물
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
SI1497440T1 (sl) * 2002-04-25 2009-02-28 Crucell Holland Bv Stabilni adenovirusni vektorji in postopki za njihovo propagacijo
WO2003099859A2 (de) * 2002-05-27 2003-12-04 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
MXPA05004074A (es) * 2002-10-15 2005-09-20 Sonne Holm Per Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
RU2393221C2 (ru) * 2002-10-15 2010-06-27 Пер Сонне ХОЛЬМ Аденовирус с обращенной генной экспрессией и его применение
WO2004083404A2 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
CA2522866A1 (en) * 2003-04-28 2005-01-20 Nanosys, Inc. Super-hydrophobic surfaces, methods of their construction and uses therefor
US20070110719A1 (en) * 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
CA2590257A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2006070024A2 (de) 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
KR20070103412A (ko) 2007-10-23
US20110286999A1 (en) 2011-11-24
KR101527213B1 (ko) 2015-06-09
SG158133A1 (en) 2010-01-29
WO2006070023A2 (en) 2006-07-06
CA2592699A1 (en) 2006-07-06
US11369650B2 (en) 2022-06-28
US20220339219A1 (en) 2022-10-27
CN101128593A (zh) 2008-02-20
CN101128593B (zh) 2014-09-03
AU2006203736B2 (en) 2012-03-29
JP2008526188A (ja) 2008-07-24
EP1831382A2 (en) 2007-09-12
US20100310554A1 (en) 2010-12-09
US20170252443A1 (en) 2017-09-07
WO2006070023A3 (en) 2006-09-21
CA2592699C (en) 2023-02-21
EP1831382B1 (en) 2023-01-18
JP5584393B2 (ja) 2014-09-03
AU2006203736A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
SG158133A1 (en) Method for reversing multiple resistance in animal cells
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
ZA200706030B (en) GLP-1 agonists, compositions, methods and uses
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
AP2289A (en) Microbial biocementation.
NO20053161D0 (no) Mikrobedrepende sammensetning.
DE602005022897D1 (de) Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
EP1912667A4 (en) CONCENTRATED PROTEIN LYOPHILISATES, ASSOCIATED METHODS AND USES THEREOF
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
FI20045162A0 (fi) Ryhmäviestintä viestinjärjestelmässä
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
ATE556446T1 (de) Batterieanoden
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
MX2008001638A (es) Metodo de espaciado de piel entumecida.
GB0413142D0 (en) Improvements in, or relating to testing
ITMI20051746A1 (it) Macchina i.s.
BR8203451Y1 (pt) disposição construtiva em copo descartável.
AU2004906102A0 (en) Softshu horseshoe Rev. I
ITFR20040018A1 (it) Antislavina & i.s.m.
UA4341U (uk) Літична суміш для проведення гібернації та гіпотермії
ES1056941Y (es) Percha multiple.
AU300905S (en) Storage unit
AU2005900374A0 (en) The fish hooka, new submission
NL1025973A1 (nl) Hengsel.
AU300898S (en) Storge unit

Legal Events

Date Code Title Description
FG Grant or registration